Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12786753 | 1.00 | HSD11B1 (1.00) | HSD11B1ACHELMNAGAAALDH1A1 | |
| SCHEMBL18381180 | 0.87 | HSD11B1 (0.77) | HSD11B1ALDH1A1 | |
| SCHEMBL12786839 | 0.87 | HSD11B1 (0.77) | HSD11B1ACHEALDH1A1 | |
| SCHEMBL30121385 | 0.83 | HSD11B1 (0.70) | HSD11B1ALDH1A1 | |
| SCHEMBL4413069 | 0.83 | HSD11B1 (0.70) | HSD11B1ALDH1A1 | |
| SCHEMBL4405981 | 0.82 | HSD11B1 (0.69) | HSD11B1 | |
| SCHEMBL31471935 | 0.81 | HSD11B1 (0.67) | HSD11B1GAAALDH1A1 | |
| SCHEMBL31471931 | 0.80 | HSD11B1 (0.67) | HSD11B1LMNAALDH1A1 | |
| SCHEMBL31472000 | 0.79 | HSD11B1 (0.65) | HSD11B1LMNAALDH1A1 | |
| SCHEMBL4403548 | 0.78 | HSD11B1 (0.64) | HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059929-A1 | SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059929-A1 | SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | HSD17B11, HSD17B1, HSD11B1 | HSD11B1 3/4885ACHE 3046/4885LMNA 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.